Alnylam Pharma (ALNY) Confirms Approval of GIVLAARI by FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Alnylam Pharmaceuticals (ALNY) PT Raised to $159 at Cantor Fitzgerald
November 21, 2019 6:54 AM ESTCantor Fitzgerald analyst Alethia Young raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $159.00 (from $150.00) while maintaining a Overweight rating.
... MoreAlnylam Pharma (ALNY) to Resume Trading at 3:30 pm
November 20, 2019 3:28 PM ESTAlnylam Pharma (NASDAQ: ALNY) to Resume Trading at 3:30 pm
... MoreAlnylam Pharma (ALNY) Plans New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI
November 20, 2019 2:43 PM ESTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is announcing today a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic porphyria (AHP) an ultra-rare orphan disease gain access to GIVLAARI (givosiran) injection for subcutaneous use, a first-of-its-kind RNAi therapeutic for the... More
FDA approves Alnylam Pharmaceuticals' (ALNY) treatment for inherited rare disease
November 20, 2019 12:35 PM ESTToday, the U.S. Food and Drug Administration granted approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood).
This buildup can cause acute attacks, known as porphyria attacks, which can lead to severe pain and paralysis, respiratory failure, seizures and mental status changes. These attacks occur... More
Alnylam Pharma (ALNY) Halted, News Pending
November 20, 2019 11:48 AM ESTAlnylam Pharma (NASDAQ: ALNY) Halted, News Pending
... More